281219-32-7

Basic information

• Product Name: Carbamic acid, 4-pentenyl-2-propenyl-, phenylmethyl ester
• CAS NO: 281219-32-7
• Molecular Formula: C16H21NO2
• Molecular Weight: 259.348
• Mol File: 281219-32-7.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Carbamic acid, 4-pentenyl-2-propenyl-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, 4-pentenyl-2-propenyl-, phenylmethyl ester(281219-32-7)
• EPA Substance Registry System: Carbamic acid, 4-pentenyl-2-propenyl-, phenylmethyl ester(281219-32-7)

Safety Data

• Hazardous Substances Data: 281219-32-7(Hazardous Substances Data)

Upstream product

• 1119-51-3 bromopentene 
• 83687-69-8 benzyl(prop-2-enyl)carbamic acid benzyl ester 
• 501-53-1 benzyl chloroformate 
• 54436-57-6 (allyl)(pent-4-enyl)amine 
• 107-11-9 1-amino-2-propene 
• 5041-33-8 N-(Benzyloxycarbonyl)allylamine 

Downstream Products

• 150989-61-0 4(R,S)-amino-3(R,S)-hydroxyazepane-1-carboxylic acid benzyl ester 
• 150989-60-9 3-Amino-1-(benzyloxycarbonyl)-4-hydroxyhexahydro-1H-azepine 

Relevant articles and documents

M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Q, X, Y, Z, R1, R7 and n are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modul

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.